Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases

Investigative Radiology

Volumn 47, Issue 7, 2012, Pages 422-429

  Merz, Maximilian ^a   Komljenovic, Dorde ^a   Semmler, Wolfhard ^a   Bäuerle, Tobias ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

angiogenesis; bone metastases; contrast enhanced ultrasound; dynamic contrast enhanced MRI; treatment response

Indexed keywords

SUNITINIB; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD VOLUME; BONE METASTASIS; BREAST CANCER; CLINICAL OBSERVATION; CONTRAST ENHANCED ULTRASOUND; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEASIBILITY STUDY; IMMUNOHISTOLOGY; IN VIVO STUDY; INOCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SHAM PROCEDURE; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; ULTRASOUND;

EID: 84862125449     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31824f635a     Document Type: Article

References (31)

1. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411-425. doi:nrc3055 [pii]. 10.1038/nrc3055.
2. Onishi T, Hayashi N, Theriault RL, et al. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:641-651. doi:nrclinonc.2010.134 [pii]. 10.1038/nrclinonc. 2010.134.
3. Maita S, Yuasa T, Tsuchiya N, et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer. 2012;130:677-684.
4. Bäuerle T, Hilbig H, Bartling S, et al. Bevacizumab inhibits breast cancerinduced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia. 2008;10:511-520. (Pubitemid 351657393)
5. Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer. 2011;47:277-286. doi:S0959-8049(10)008427 [pii]. 10.1016/j.ejca. 2010.08.019.
6. Bäuerle T, Merz M, Komljenovic D, et al. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res. 2010;16:3215-3225. doi:1078-0432.CCR-09-2932 [pii]. 10.1158/1078-0432.CCR-09-2932.
7. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953. doi:10.1200/JCO.2004.08.181. 22./14/2942 [pii]. (Pubitemid 41079914)
8. Bäuerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol. 2009;19:2495-2507. doi:10.1007/s00330-009-1443-1.
9. Hamaoka T, Costelloe CM, Madewell JE, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102:651-657. doi:6605546 [pii]. 10.1038/sj.bjc. 6605546.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247. doi:S0959-8049(08)00873-3 [pii]. 10.1016/j.ejca. 2008.10.026.
11. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348-364. doi:256/2/348 [pii]. 10.1148/radiol. 10091760.
12. Bäuerle T, Bartling S, Berger M, et al. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol. 2010;73:280-287. doi:S0720-048X(08)00578-0 [pii]. 10.1016/j.ejrad. 2008.10.020.
13. Paik SH, Chung MJ, Park JS, et al. High-resolution sonography of the rib: can fracture and metastasis be differentiated? AJR Am J Roentgenol. 2005;184:969-974. doi:184/3/969 [pii]. (Pubitemid 43899530)
14. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrastenhanced ultrasonography. Clin Cancer Res. 2010;16:1216-1225. doi:1078-0432.CCR-092175 [pii]. 10.1158/1078-0432.CCR-09-2175.
15. Williams R, Hudson JM, Lloyd BA, et al. Dynamic microbubble contrastenhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology. 2011;260:581-590.
16. Bäuerle T, Adwan H, Kiessling F, et al. Characterization of a rat model with sitespecific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer. 2005;115:177-186. doi:10.1002/ijc.20840. (Pubitemid 40586725)
17. Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:621-628.
18. Zwick S, Brix G, Tofts PS, et al. Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI. Eur Radiol. 2010;20:432-442. doi:10.1007/s00330-00915566.
19. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593. doi:10.1038/nrc867. nrc867 [pii]. (Pubitemid 37328925)
20. Stieger SM, Dayton PA, Borden MA, et al. Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. Contrast Media Mol Imaging. 2008;3:9-18. doi:10.1002/cmmi.224. (Pubitemid 351493974)
21. Chen WT, Shih TT, Chen RC, et al. Blood perfusion of vertebral lesions evaluated with gadolinium-enhanced dynamic MRI: in comparison with compression fracture and metastasis. J Magn Reson Imaging. 2002;15:308-314. doi:10.1002/jmri.10063 [pii]. (Pubitemid 34195127)
22. Northam M, de Campos RO, Ramalho M, et al. Bone metastases: evaluation of acuity of lesions using dynamic gadolinium-chelate enhancement, preliminary results. J Magn Reson Imaging. 2011;34:120-127. doi:10.1002/jmri.22495.
23. Montemurro F, Russo F, Martincich L, et al. Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol. 2004;45:71-74.
24. Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009;72:217-238. doi:S1040-8428(08)00153-4 [pii]. 10.1016/j.critrevonc. 2008.07.012.
25. Kiessling F, Krix M, Heilmann M, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol. 2003;38:516-524. doi:10.1097/01.rli.0000073448.16334.fe. (Pubitemid 36875548)
26. Watson KD, Hu X, Lai CY, et al. Novel ultrasound and DCE-MRI analyses after antiangiogenic treatment with a selective VEGF receptor inhibitor. Ultrasound Med Biol. 2011;37:909-921. doi:S0301-5629(11)00136-0 [pii]. 10.1016/j.ultrasmedbio. 2011.03.001.
27. Pysz MA, Foygel K, Panje CM, et al. Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging. Invest Radiol. 2011;46:187-195. doi:10.1097/RLI.0b013e3181f9202d.
28. Gianfelice D, Gupta C, KucharczykW, et al. Palliative treatment of painful bone metastases with MR imagingYguided focused ultrasound. Radiology. 2008;249:355-363. doi:2491071523 [pii]. 101148/radiol. 2491071523.
29. Bzyl J, Lederle W, Rix A, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol. 2011;21:1988-1995.
30. Pysz MA, Foygel K, Rosenberg J, et al. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology. 2010;256:519-527. doi:radiol.10091858 [pii]. 10.1148/radiol. 10091858.
31. Anderson CR, Hu X, Zhang H, et al. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol. 2011;46:215-224. doi:10.1097/RLI.0b013e3182034fed.